Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solutio
I6T-MC-AMCA
Approved small_molecule active
Quick answer
Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solutio for severely active ulcerative colitis (US) and CD (Crohn’s disease) is a Approved program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- severely active ulcerative colitis (US) and CD (Crohn’s disease)
- Phase
- Approved
- Modality
- small_molecule
- Status
- active